Translate
Giving
Menu
Search

CIT Clinical Trials - Actively Enrolling Trials

More Information

To participate in any of these studies or for more information, please call 858-657-7040.

Lupus (SLE)

  • Biogen Idec - A Multicenter, Randomized, Double-blind, Placebo-controlled study to evaluate the efficacy, safety and Tolerability of BIB023 in subjects with Lupus Nephritis
  • Exagen – Cell bound complement activation products for the monitoring of Systemic Lupus Erythematosus
  • HGS – A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Belimumab plus standard of care versus placebo plus standard of care in adult subjects with Active Lupus Nephritis
  • Human Genome Sciences, Inc – A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled, 52-Week study to evaluate the efficacy and safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to subjects with Systemic Lupus Erythematosus (SLE)
  • ITN – A Randomized, Double-blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis.
  • Kirin – In vitro immunomodulation of SLE (lupus) patient PBMC and biomarker analysis
  • MedImmune – A Phase 2, Randomized study to evaluate the efficacy and safety of MEDI-546 in subjects with Systemic Lupus Erythematosus
  • Novo Nordisk – A randomized, placebo-controlled, double-blind, multiple-dose, dose-escalation trial investigating the safety and tolerability of NNC0114-0006 in subjects with Systemic Lupus Erythematosus
  • Pfizer - A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging study to evaluate the efficacy and safety of Pf-04236921in subjects with Systemic Lupus Erythematosus (SLE)
  • Quest Pharmaceuticals, Inc – A two-part study exploring the efficacy, safety, and pharmacodynamics of Acthar in systemic lupus erythematosus patient with a history of persistently active disease.
  • UCB – A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter study of the efficacy and safety of Four 12-week treatment cycles (48 weeks total) of Epratuzumab in Systemic Lupus Erythematosus subjects with moderate to severe disease (EMBODY 2)

Rheumatoid Arthritis (RA)

  • Astellas – A Phase 2,open-label, Non-comparative, Multicenter extension study to evaluate the long-term safety and efficacy of ASP015K in subjects previously enrolled in a phase 2 ASP015K Rheumatoid Arthritis study.
  • Astellas – A Phase 2b, Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Dose-finding, Monotherapy, MultiCenter study to evaluate the safety and efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects
  • Astellas – A Phase 2b, Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Dose-finding, Multicenter study to evaluate the safety and efficacy of ASP015K in Moderate to severe Rheumatoid Arthritis subjects who have had an Inadequate response to Methotrexate.
  • Janssen – A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in subjects with Active Rheumatoid Arthritis Despite Anti-TNFα Therapy .
  • Janssen – A Mulitcenter, Randomized, Double-blind, Placebo-controlled, Parallel group study of CNTO 136 (sirukumab), a Human Anti-IL-6 Moncolonal Antibody, Administered Subcutaneously, in subjects with Active Rheumatoid Arthritis Despite DMARD Therapy.

Ankylosing Spondylitis (AS)

  • Celgene – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-Group study to evaluate the efficacy and safety of Apremilast (CC-10004) in the treatment of Active Ankylosing Spondylitis.

Scleroderma (PSS)

  • Roche – A Phase II/III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of Tocilizumab versus placebo in patients with Systemic Sclerosis

Gout

  • Ardea Biosciences, Inc – A Phase 3 randomized, double-blind, multicenter, placebo-controlled, combination study to evaluate the efficacy and safety of Lesinurad and Febuxostat compared to Febuxostat alone at lowering serum uric acid and resolving Tophi in subjects with Tophaceous Gout
  • Ardea Biosciences, Inc – A Phase 3 randomized, double-blind, multicenter, placebo-controlled, combination study to evaluate the efficacy and safety of Lesinurad and Allopurinol compared to Allopurinol alone in subjects with Gout who have had an Inadequate Hypouricemic response to standards of care Allopurinol
  • Ardea: A novel uricosuric in gout patients on or not on other therapies